GSK2618960 + methotrexate

This drug is a **combination of GSK2618960 and methotrexate**. - **GSK2618960** is a humanized monoclonal antibody targeting the interleukin-7 receptor alpha subunit (CD127). It acts as an antagonist, inhibiting IL-7-mediated signaling involved in T cell activity, which is implicated in autoimmune diseases. GSK2618960 showed good receptor occupancy, modulates STAT5 phosphorylation, and has a relatively short half-life due to target-mediated clearance. It is under evaluation for autoimmune diseases[6][2]. - **Methotrexate** is a well-established small molecule antimetabolite and antifolate commonly used as a disease-modifying antirheumatic drug (DMARD), inhibiting dihydrofolate reductase and many cellular functions, particularly in autoimmune and oncologic indications. There is currently **no documentation of this specific combination being in clinical trials or approved** as a combination product, but both agents are plausible for combined use in autoimmune conditions (notably rheumatoid arthritis) based on their mechanisms and common combination strategies with other biologicals.